We previously have shown that platelet-derived growth factor (PDGF) modulates the biological activity of extracellular vesicles released by adipose-derived mesenchymal stem cells (ASC-EVs). ASC-EVs may interact with blood and vessel cells by transferring proteins and nucleic acids and regulate their functions. In this study, we investigated immunomodulatory activity and protection from acute hindlimb ischemia of EVs released by PDGF-stimulated ASC (PDGF-EVs). PDGF treatment of ASC changed protein and RNA composition of released EVs by enhancing the expression of antiinflammatory and immunomodulatory factors. In vitro, control EVs (cEVs) derived from non-stimulated ASC increased the secretion of both the IL-1b, IL-17, IFNγ, TNFα pro-inflammatory factors and the IL-10 anti-inflammatory factor, and enhanced the in vitro peripheral blood mononuclear cell (PBMC) adhesion on endothelium. In contrast, PDGF-EVs enhanced IL-10 secretion and induced TGF-β1 secretion by PBMC. Moreover, PDGF-EVs stimulated the formation of T regulatory cells. In vivo, PDGF-EVs protected muscle tissue from acute ischemia, reduced infiltration of inflammatory cells and increased T regulatory cell infiltration in respect to cEVs. Our results suggest that PDGF-EVs are enriched in anti-inflammatory and immunomodulatory factors and induced in PBMC an enhanced production of IL-10 and TGF-β1 resulting in protection of muscle from acute ischemia in vivo.
Angiogenesis, tissue repair and inflammation are closely related processes. In this study aimed to define the effect of ASC-derived EVs, released in response to PDGF stimulation (PDGF-EVs), in tissue regeneration and inflammation. For this purpose, we compared the in vitro effect of control EVs (cEVs) and PDGF-EVs on peripheral blood mononuclear cells (PBMC). We compared protein and RNA composition of PDGF-EVs and cEVs and the effect of PBMC stimulation by these EVs. In particular, the cytokine secretion, PBMC differentiation and activation, and PMBC adhesion to endothelium were evaluated. In vivo, we investigated the effects of PDGF-EVs and cEVs on injured muscles using a model of acute hindlimb ischemia in mice.
Results
Characterization of PDGF-EVs. To validate our previous data 5 , we confirmed no difference in EV size (90 nm) and morphology between cEVs and PDGF-EVs according to electron microscopy and nanoparticle tracking analysis (NTA) ( Fig. 1a-d ). Similar to our previous result PDGF stimulation significantly enhanced EV release 5 according to the expression of exosomal markers CD63 and CD81 validated by ELISA ( Fig. 1e ). FACS analysis confirmed that the PDGF-EV population was significantly enriched in CD63 + (15.3% ± 6.8 of cEVs, vs. 27.7% ± 14.3 of PDGF-EVs, p = 0.045, Fig. 1g ), CD81 + (26.5% ± 8.9 of cEVs, vs. 64.9% ± 12.3 of PDGF-EVs, p = 0.039, Fig. 1h ), and phosphatidylserine positive particles (47.5% ± 13.8 of cEVs, vs. 76.8% ± 9.8 of PDGF-EVs, p = 0.028, Fig. 1i ).
The expression of CD47 (32.8% ± 16, Supplementary Fig. S1c ), CD105 (62.2% ± 11.4, Supplementary  Fig. S1d ), HLA class I (37.6% ± 8, Supplementary Fig. S1e ), HLA class II (0.8% ± 4, Supplementary Fig. S1f ), ICAM (35% ± 14.4, Supplementary Fig. S1g ), and VE-cadherin (52.9% ± 9.4, Supplementary Fig. S1h ), was not statistically different even if an enhanced expression trend was observed in PDGF-EVs. PDGF did not change the expression of CD105, HLA, and VE-cadherin, which are markers of the cell of origin, and of ICAM and CD4, which are ubiquitously expressed molecules. PDGF-EVs contain a unique composition of proteins related to inflammation and tissue regeneration. Using protein array, we have evaluated the expression of 1,000 proteins in PDGF-EVs and their controls in two independent experiments. The only proteins consistently up-or down-regulated were considered differentially expressed. Thus, we found 65 proteins to be consistently up-regulated, 15 proteins to be consistently down-regulated in PDGF-EVs relative to their non-stimulated EV controls. We have also detected 228 proteins with an equal expression (RQ more than 0.5 and less than 2) between PDGF-EVs and cEV ( Supplementary  Table S1 , Fig. S2 ). The bioinformatic analysis of EV proteins revealed that both populations of EVs carried regulators of inflammation, but PDGF-EVs were significantly enriched with proteins implicated in immunomodulation such as TGFβ1, TRAIL, TROY, CCR7, CD71, CXCL11, LTBP, TLR4, TGFBR3, TNFSF8, TNFSF10, IL-23A, CD38,  GLYPICAN 5 , ADAMTS, and proteins involved in pro-regenerative process such as VEGFs, BDNF, FGF21. On the other hand, PDGF-EVs were diminished of Activin, TNFRSF13C, CD80, angiopoietin-like 2, and RIP1, known to promote inflammation ( Supplementary Fig. S3b ).
PDGF-EVs contain a unique composition of RNA molecules.
We performed PCR array analysis of long non-coding (lnc) RNA and microRNA in PDGF-EVs and cEVs. This analysis revealed that PDGF-EVs contained significantly more lncRNA MALAT1 (RQ 5.1, p = 0.013) a well-described anti-inflammatory 12 , pro-angiogenic 13 , and pro-regenerative regulator 12, 14, 15 .
MicroRNA analysis also revealed a significant difference in the expression of several miRNAs: PDGF-EVs carry significantly more miR-502 (RQ = 16.5, p = 0.042), miR-99a (RQ = 6.0, p = 0.03), miR-203 (RQ = 2.1 p = 0.017), miR-125 (RQ = 2.4, p = 0.031), and miR-195 (RQ = 2.4, p = 0.034), and were depleted of miR-1225 (RQ = 0.3, p = 0.05) and miR-1226 (RQ = 0.5, p = 0.005). Several microRNA were detected exclusively in cEVs or in PDGF-EVs ( Supplementary Table S2 ). EV expression of MALAT1, miR-29a, miR-126-3p, miR-92a-3p, and miR-145-5p was independently confirmed by Real-time PCR ( Supplementary Fig. S3 ). Bioinformatic analysis performed using DIANA TOOL mirPath V3 16 revealed that PDGF-EVs carried miRNAs that potentially target TNFα (miR-551b-3p), inhibitors of TGF-β signaling pathway (miR-let7f-2-3p), and pseudoreceptor BAMBI, a negative regulator of TGF-β (miR-99a-3p). On the other hand, cEV carried miRNAs that potentially target precursor of TGF-β LTBP1 (miR-1, miR-541-3p, and miR-659-3p) and SMAD4 (miR-483-3p). Overall, PDGF-EVs contained miRNAs implicated in TGF signaling and TNF signaling, whereas cEVs overrepresented fatty acid metabolism pathways ( Supplementary Table S3 ).
PDGF-EVs possess anti-inflammatory properties. PDGF-stimulated and non-stimulated ASC-EVs
contain distinct patterns of proteins and RNA molecules, relevant to inflammation. We, therefore, investigated the influence of these EVs on inflammatory cells in vitro.
Using FACS analysis, we evaluated the ability of PKH67GL-labeled EVs to be internalized by PBMC ( Fig. 2b ). As shown in Fig. 2a , EVs were preferentially internalized into the monocyte fraction of PBMC. Moreover, PDGF-EVs were internalized significantly faster into the monocytes than cEVs ( Fig. 2a ). Both types of EV stimulated PBMC proliferation ( Fig. 2c ) and increased the number of CD25 + cells (Fig. 2d ). The number of CD8 + , CD20 + or CD19 + did not change upon EV stimulation. Both types of EVs induced the expression of PDL1 on monocytes. PDGF-EV decreased the expression of CD11b, whereas, cEVs significantly enhanced the expression of the monocyte activation markers CD80 and CD127 ( Fig. 2d ).
To evaluate the effect of EVs on PBMC gene expression, we performed PCR array-based gene expression analysis of 84 genes involved in inflammation. The cEVs led to significant up-regulation of 10 pro-inflammatory genes (CCL1, CCL2, CCL7, CXCL1, CXCL2, CXCL3, CXCL5, CXCL8, and NAMPT). Interestingly, NAMPT is involved in endothelial inflammation recruiting leukocyte and inducing vascular smooth muscle inflammation 17 .
GAPDH, a marker of T cell activation 18 , was significantly down-regulated after stimulation with both types of EVs, but PDGF-EVs decreased its expression significantly more than cEVs (RQ 0.3 vs. cEVs, p = 0.049). PDGF-EV also significantly down-regulated MIF expression that has been described to induce a pro-inflammatory response 19 .
PDGF-EVs significantly up-regulated CSF (RQ 2.3 vs. control PBMC, p = 0.009) and lncRNA MALAT1 (RQ 2.4 vs. control PBMC, p = 0.021) expression in PBMC.
The data from PCR arrays suggest that both types of EVs activated PBMC, but stimulation with PDGF-EVs could induce an anti-inflammatory phenotype. To confirm this hypothesis at the protein level, we performed the analysis of several cytokines by ELISA. This analysis revealed that cEVs significantly enhanced the production of pro-inflammatory factors IFNγ, IL-1b, IL-17, and TNFα by PBMC, whereas PDGF-EVs did not ( Fig. 3a-d ). Both types of EVs up-regulated the secretion of IL-10, but PDGF-EVs enhanced it significantly more (RQ 1.6 vs. cEVs, p = 0.002) relative to cEVs ( Fig. 3f ). PDGF-EVs also significantly increased TGF-β1 production by PBMC, whereas cEVs did not ( Fig. 3e ).
PDGF-EVs decrease PBMC adhesion on endothelium and promote Treg formation.
As was mentioned before, cEVs induced the expression of NAMPT in PBMC, which is described as a factor implicated in leukocyte adhesion on endothelium. On the other hand, TGF-β1 and IL-10, up-regulated by PDGF-EVs, are described as factors able to reduce PBMC adhesion on endothelium [20] [21] [22] . To evaluate whether PDGF-EVs modulate the adhesion of labeled PBMC to the endothelium, we pre-incubated separately overnight PBMC and human umbilical vein endothelial cells (HUVEC) with ASC-EVs. PBMC and HUVEC were then co-incubated, and PBMC adhesion was evaluated. We found that cEVs significantly enhanced PBMC adhesion on HUVEC, whereas PDGF-EVs significantly decreased it ( Fig. 4a ).
Since PDGF-EVs enhanced secretion of TGF-β1 and IL-10, known to induce Treg differentiation and activation 23 CD127 − lymphocyte populations in PBMC treated with PDGF-EV relative to cEVs (Fig. 4b,c ) was observed. We confirmed the functional activity of Treg by the test of activated T cells proliferation inhibition ( Fig. 4d ).
PDGF-EVs protect muscles from acute ischemic injury and decrease inflammation in vivo.
To investigate the role of PDGF-EVs in vivo we used a mouse model of acute hindlimb ischemia. As shown in Fig. 5 , PDGF-EVs significantly enhanced blood perfusion detected by Laser Doppler relative to cEVs ( Fig. 5a,b ). Increased angiogenesis was confirmed by the staining of CD31 + cells within muscles. The most relevant effect of PDGF-EVs was observed on muscle tissue protection from ischemia and on inhibition of monocyte infiltration. The histological analysis of gastrocnemius muscles 7 days after the induction of hindlimb ischemia revealed that the mice treated with vehicle or cEVs were characterized by diffuse necrotic area and by an intensive inflammatory cell infiltration (CD14 + cells) in the injured muscle tissue. In contrast, muscles of animals treated with PDGF-EVs were almost normal with regular centronucleated muscle fibers in more than 90% of the muscle cross-sections ( Fig. 6a,b ). Infiltration of CD14 + cells was significantly reduced in PDGF-EV treated animals ( Fig. 6c,d) . Moreover, only in muscles obtained from PDGF-EV treated mice were detected few Treg (Fig. 6e ).
Discussion
After tissue injury, the switch from inflammation to immunosuppression is linked to the enhanced concentration of PDGF 8 and to the increased number and activity of Treg 24 . It was previously shown that PDGF could increase Treg formation through dendritic cells induction 25 . Mesenchymal stem cells and, in particular, ASC express the high level of PDGF receptors. Our data suggested that PDGF, known to regulate ASC pro-angiogenic and pro-regenerative properties, could also modulate the immunomodulatory characteristics of ASC.
Pro-inflammatory and anti-inflammatory properties of ASCs have been reported. ASCs from healthy subjects were reported to have anti-inflammatory pro-regenerative properties when administered in different disorders [26] [27] [28] [29] [30] . On the other hand, obesity, diabetes, and chronic inflammation, as well as culture conditions, may transform the phenotype of these cells from anti-inflammatory to pro-inflammatory 31, 32 . Moreover, the pro-angiogenic potential of ASC-EVs was shown to be impaired by obesity 33 . Therefore, the environmental conditions may modulate the biological activity of both ASC and ASC-derived EVs 34 .
In the present study, we found that ASC derived from patients undergoing non-neoplastic elective surgery in basal culture conditions have a molecular profile characterized by the expression of both pro-inflammatory and anti-inflammatory molecules. This balance was changed by ASC stimulation with PDGF. In fact, PDGF induced enrichment in ASC-EVs of anti-inflammatory and immunomodulatory proteins such as TGF-β1 and IL-10. ( Supplementary Table S1 and Fig. S3b ).
The comparative analysis of miRNA pattern of cEVs and PDGF-EVs showed enrichment of miRNAs relevant to immunomodulation (TGF and TNF signalings) in PDGF-EVs, whereas cEVs contained more miRNAs regulating fatty acid metabolism. By comparison of miRNA patterns with the protein content of EVs, we found several potential reciprocal pairs miRNA-target proteins. For example, cEVs contain miR-1 and miR-299 and reduced expression of target VEGF and TIMP3. In contrast, PDGF-EVs that did not express miR-1 and miR-299 showed an increased expression of VEGF and TIMP3. On the other hand, cEV but not PDGF-EVs carried miRNAs that potentially target precursor of TGF-β LTBP1 (miR-1, miR-541-3p, and miR-659-3p), which was hyper-expressed in PDGF-EVs. Both types of ASC-EVs, cEVs and PDGF-EVs, carried proteins, known to activate immune cells, such as TLRs, interleukins and their receptors, IFNγ, CSFs, PlGF, CRP, and others (see Supplementary Table S2 ).
In comparison with cEVs, PDGF-EVs could induce the secretion of anti-inflammatory factor TGF-β1 by PBMC and to decrease the secretion of pro-inflammatory factors IL-1b, IL-17, IFNγ, and TNFα. Moreover, we had noticed that cEVs significantly enhanced in vitro PBMC adhesion on endothelium, probably by increasing NAMPT expression 17 , whereas PDGF-EVs inhibited it.
Transient activation of immune cells and inflammation may be beneficial in vivo since may promote angiogenesis and tissue regeneration. However, an unbalance between the pro-inflammatory and anti-inflammatory molecules may be detrimental. Taken together, our results suggest that PBMC activation by ASC-EVs is a normal reaction, but PDGF stimulation shift the EV phenotype to a more anti-inflammatory phenotype.
Indeed, in vivo cEVs increased the infiltration of CD14 + cells in the injured tissue. However, since we sacrificed the animals on day 7, we may have missed a stronger initial inflammatory response. At variance of cEVs, PDGF-EVs significantly decreased the infiltration of CD14 + cells in injured tissue and induced the formation of Treg. Studies in the literature indicate that muscle tissue regeneration is linked to immune suppression and Treg functions 24, 35 . Our data suggested that PDGF-EVs, which carried TGF-β1 and lncRNA MALAT1 and induced their expression in PBMC, could protect muscle tissue from ischemic injury since these factors are involved in Treg formation [36] [37] [38] [39] [40] [41] . We also demonstrated that PDGF-EVs expressed significantly more TRAIL and TROY, which could induce apoptosis of activated CD8 + T cells and reduce immune response 42 . On the other hand, cEVs carried miR-1204, miR-1272, miR-1, and miR-330-5p that could target TGF-β1 according to miRwalk. We suggested that cEV attracted immune cells and activated them, thus inducing regenerative process in the injured tissue, whereas PDGF-EVs protected muscle tissue from ischemia restoring blood supply and limiting inflammation. In conclusion, our study demonstrated that secretion of ASC-derived EVs could be regulated by PDGF, changing both protein and RNA composition and their functions.
Materials and Methods
Isolation of ASC-EVs before and after PDGF stimulation. ASCs were isolated by enzyme digest as described previously 43 . Briefly, subcutaneous fat tissue from 6 patients submitted to non-neoplastic elective abdominal surgery (1 female and 5 males, mean age 51 ± 8) was washed in sterile PBS and was minced into pieces of 2 mm in diameter in a Petri dish. The minced tissues were transferred to a conical tube along with 220 U/mL collagenase I type (Worthington Biochemical, Lakewood, NJ), and 40 U/mL dispase (Invitrogen Corporation, Germany). The tissue was digested at 37 °C for 30 min with constant mixing. Enzyme activity was neutralized with DMEM, containing 10% fetal bovine serum (FBS, Lonza), 100 units/ml penicillin, 0.1 mg/ml streptomycin, and 0.25/ml μg amphotericin B (antibiotic/antimycotic solution, Sigma). The digested suspension was centrifuged at 900 g for 10 min to obtain a high-density stromal vascular fraction pellet. The cell pellet was resuspended in MSCBM complete medium (Lonza) and cultured at 37 °C in 5% CO 2 incubator. After two days the medium was changed, and the cells were cultivated until 100% confluency (normally reached in 4-5 days). ASC characterization was performed by FACS analysis for the positive expression of mesenchymal markers (CD105, CD73, CD90), negative expression of hematopoietic markers (CD31) and by differentiation into adipogenic, osteogenic, and chondrogenic phenotypes as previously described 5, 44 . For our experiments, we used cells after 2-8 passages.
For EV isolation ASCs were cultured in FBS-free DMEM for 18 hours. After washing, the cells were incubated in fresh FBS-free DMEM supplemented or not with PDGF (PDGFbb, Peprotech, 20 ng/ml) for additional 6 hours. Cells were then extensively washed to remove PDGF and fresh FBS-free DMEM was added, and cell-free conditioned medium for EV collection was obtained after 24-hour incubation by 300 g centrifugation 30 minutes at room temperature. To remove cell debris and apoptotic bodies cell-free supernatant was submitted to further centrifugation at 3000 g for 30 minutes at room temperature. Previously we showed that 10,000 g and 100,000 g fractions of EVs did not show a significant difference in the biological activity 4,45 therefore we decided to use a total 100,000 g fraction for further experiments. Supernatants were submitted to ultracentrifugation twice for 2 hours at 100,000 g at 4 °C using the Beckman Coulter Optima L-100K Ultracentrifuge with the rotor type 45 Ti 45000RPM. The EV pellet was resolved in DMEM supplemented with 1% of DMSO, filtered with PES membrane filters (0.22 μm, Millipore) and then stored at −80 °C until further use. After thawed, EV aliquots were resuspended in PBS and analyzed using the Nanoparticle tracking analysis (NTA) by NanoSight NS300 system (Malvern Instruments, Ltd) to determine particle concentrations. NTA is a method of visualization and analysis of particles in liquids, by relating the rate of Brownian motion to particle size. Isolated particles were visualized by the light they scatter when illuminated by laser light. The rate of particle movement was linked to the size of the particles. Each sample was run in triplicate on different file recorded for 30 seconds and results were expressed as the mean of the three determinations. EVs were also analyzed by FACS (CytoFlex, Beckman Coulter), western blot and transmission electron microscopy.
FACS analysis of EVs.
A pool of approximately 5 × 10 10 particles/100 μl was incubated with antibodies for 30 minutes at 4 °C. Then the final volume was increased to 500 μl and FACS analysis was performed at a low flow rate, with 10,000 events using CytoFlex from Beckman Coulter. The instrument was calibrated with Cytoflex Daily QC Fluorospheres according to the manufacturer's instructions followed by Megamix-Plus FSC reagent (0.1, 0.3, 0.5, and 0.9 µm; Biocytex; Diagnostica Stago) and FlowCount beads. The used antibodies were specific for CD63 (FITC, BD, Pharmigen, #557288), CD81 (PE, BD Pharmigen, #555676), CD105 (FITC, Miltenyi, #130-098-774), ICAM (BD Pharmigen, #559771), VE-cadherin (FITC, BD Pharmigen, #560874), CD47 (FITC, BD Pharmigen,#556044), HLA class I (PE, BD Pharmigen, #560964), HLA class II (FITC, BD Pharmigen, #347400), Annexin V (FITC, Bender, #BMS306FI) was used for the characterization of EVs. Buffer alone with antibodies was analyzed prior to sample acquisition to ensure that any background noise was eliminated from the gates ELISA assay. Relative quantification of CD63-and CD81-positive EVs was performed using the ELISA assay.
Briefly, the suspensions of EVs, collected from an equal quantity of non-stimulated or PDGF-stimulated ASC, were incubated overnight at 4 °C on protamine sulfate coated 96 well plates (Cosmo Bio Co, LTD). According to NTA 1 × 10 7 particles/100 μl was added per well. After washing with PBS, wells were stained with biotinylated antibodies against to CD63 (Miltenyi, #130-100-168) or CD81 (Miltenyi, #130-107-918).
Protein array. For protein array, 400 ml of conditioned media from an equal amount of non-stimulated or PDGF-stimulated ASC was used. Purified cEVs and PDGF-EVs were lysed in an equal volume of 2x Cell Lysis Buffer (RayBiotech, Inc), and aliquots (1000 ng of protein measured by BCA Protein Assay Kit, Thermofisher) were used for the protein array according to manufacturer instructions for AAH-BGL-100004 Human L1000, Glass Slide (RayBiotech). The array provides detection of 1000 secreted proteins. We performed two independent experiments, comparing two different samples of cEVs and PDGF-EVs. Proteins, which RQ (PDGF-EV vs. cEVs) was higher than 2 in both experiments, were considered as consistently up-regulated (65 proteins). Proteins, which RQ was lower than 0.5 in both experiments, were considered as consistently down-regulated (15 proteins). Proteins consistently expressed with RQ between 0.5 and 2 were described as equally expressed proteins (228 proteins, Supplementary Table S1 ). Proteins that were detected up-regulated in one experiment and down-regulated in the other were not taken into consideration. Bioinformatic analysis of up-or down-regulated proteins was performed using Reactome (https://reactome.org).
RNA extraction and cDNA synthesis. Total Table 2 ). Analysis of differential expression was performed using Expression Suite Software (ThermoFisher). For the further bioinformatics analysis, we selected miRNAs expressed exclusively in control or PDGF-EVs at a high level (Ct < 31) or significantly up-regulated in some of these types of EVs (in bold, Supplementary Table S2 ). Bioinformatic analysis was performed using the Diana tool mirPath V3 (http://snf-515788.vm.okeanos.grnet.gr) or miRWalk software (http://mirwalk.umm.uni-heidelberg.de). KEGG pathways and GO groups overrepresented by miRNAs from cEVs or PDGF-EVs are shown in Supplementary Table S3 .
Long non-coding RNA analysis of EVs. Profile of the lncRNA content of ASC-released EVs was carried out using the SBI's LncProfilers qPCR kit. To enhance qPCR assay performance, the cDNA synthesis kit includes a step of polyadenylation of all the lncRNAs before cDNA conversion using the tagged oligo dT adaptor and random primers. This combined RNA tailing and oligo dT plus random primers boosts cDNA yield significantly and enables strand-specific lncRNA qPCR. A profile of 96 lncRNAs was performed using the QuantStudio 12 K Flex instrument. Three endogenous genes (GAPDH, Actin, and Laminin) and two RNU (RNU-43 and RNU-6b), used as controls, were present in each plate. Analysis of differential expression was performed using Expression Suite Software (ThermoFisher).
qRT-PCR was used to confirm some miRNAs screened by microarray analysis ( Supplementary Fig. S3 ). Briefly, 200 ng of input RNA from all samples were reverse transcribed with the miScript Reverse Transcription Kit. cDNA was used to detect and quantify RNA of interest by qRT-PCR using the miScript SYBR Green PCR Kit (all from Qiagen, Valencia, CA, USA). All samples were run in triplicate using 3 ng of cDNA for each reaction as described by the manufacturer's protocol (Qiagen). miRNA specific primers to miR-29a, miR-21-5p, miR-126-3p, miR-92a-3p, miR-145-5p, or lncRNA MALAT1 were used in separate reactions. Specific primers were provided from the primer bank (https://pga.mgh.harvard.edu/primerbank/). miRNA comparison between the two types of EVs was performed on the relative expression data normalized using the geometric mean value of 2 housekeeping genes (RNU6b and actin). Fold change in miRNA expression was calculated based on the normalized mean differences between different types of EVs (2−ΔCt). miRNAs with a raw Ct value greater than 35 were not included in the final data analysis.
PBMC stimulation with ASC-EVs. The fresh PBMC were isolated by the density gradient centrifugation from heparinized blood samples obtained from eight healthy donors. PBMC were seeded in 6 well plates at a density of 10 × 10 6 /ml per well in serum-free AIM V medium. ASC-EVs were added to culture PBMC in the concentration of 1 × 10 10 /ml (approximately 1 × 10 3 EV/cell) for 48 hours. As a control, we used PBMC stimulated with an equal amount of serum-free RPMI medium. After 48 hours the cultured PBMC and conditioned media were harvested for FACS, PCR and ELISA.
EV internalization in PBMC.
Control EVs or PDGF-EVs was labeled with PKH67GL green fluorescent cell linker (Sigma) dye for 30 min at 37 °C and then washed and ultracentrifuged at 100,000 g for 1 h at 4 °C. These labeled EVs were added to PBMCs (1 × 10 3 EV/cell) for different times (10, 30 minutes, 1, 3 or 24 hours). The internalization of EVs into PBMCs was evaluated by FACS (CytoFlex, Beckman Coulter).
Analysis of proliferation, gene expression and cytokine secretion by PBMC, stimulated with PDGF-EVs or cEVs.
For proliferation test, FACS, and analysis of gene expression non-labeled EVs were used.
The proliferation of PBMC was measured by cell counting and Cell Proliferation ELISA, BrdU (colorimetric) kit (Roche, 11647229001) according to manufacturer instructions.
